A Placebo-Controlled, Double-Blind Randomized (Phase IIB) Trial of Oral Administration with HPV16 E7-Expressing <i>Lactobacillus</i>, GLBL101c, for the Treatment of Cervical Intraepithelial Neoplasia Grade 2 (CIN2)

A Placebo-Controlled, Double-Blind Randomized (Phase IIB) Trial of Oral Administration with HPV16 E7-Expressing <i>Lactobacillus</i>, GLBL101c, for the Treatment of Cervical Intraepithelial Neoplasia Grade 2 (CIN2)

Cervical intraepithelial neoplasia (CIN), a precursor lesion to cervical cancer, is caused by high-risk human papillomavirus (HPV); high-grade CIN lesions (CIN2-3) are precancerous and require treatment. No globally approved therapy is available for CIN2-3 treatment. This study is a placebo-controll...

Full description

Bibliographic Details
Main Authors: Yuji Ikeda, Katsuyuki Adachi, Kensuke Tomio, Satoko Eguchi-Kojima, Tetsushi Tsuruga, Mayuyo Uchino-Mori, Ayumi Taguchi, Atsushi Komatsu, Takeshi Nagamatsu, Katsutoshi Oda, Ai Kawana-Tachikawa, Yukari Uemura, Shizunobu Igimi, Yutaka Osuga, Tomoyuki Fujii, Kei Kawana
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Vaccines
Subjects:
Human Papillomavirus (HPV)
therapeutic vaccine
mucosal immunity
Cervical Intraepithelial Neoplasia 2 (CIN2)
cervical cancer
lactobacillus-based vaccine
Online Access:https://www.mdpi.com/2076-393X/9/4/329

Internet

https://www.mdpi.com/2076-393X/9/4/329

Similar Items